(CORT) Corcept Therapeutics - Ratings and Ratios
Hyperglycemia, Cushings, Relacorilant, Dazucorilant, Miricorilant
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 55.6% |
| Value at Risk 5%th | 70.5% |
| Relative Tail Risk | -22.88% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.64 |
| Alpha | 23.66 |
| CAGR/Max DD | 1.30 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.206 |
| Beta | 1.237 |
| Beta Downside | 1.374 |
| Drawdowns 3y | |
|---|---|
| Max DD | 45.51% |
| Mean DD | 17.50% |
| Median DD | 14.77% |
Description: CORT Corcept Therapeutics November 03, 2025
Corcept Therapeutics (NASDAQ:CORT) is a U.S.-based biopharma focused on developing and commercializing medicines for severe endocrine-related disorders. Its only FDA-approved product, Korlym (mifepristone), treats hyperglycemia secondary to endogenous Cushing’s syndrome in adults who are ineligible for or have failed surgery. The pipeline spans multiple phases: relacorilant is in Phase III for hypercortisolism and in a separate Phase III trial combined with nab-paclitaxel for platinum-resistant ovarian cancer; early-stage programs target adrenal cancer, prostate cancer, ALS (dazucorilant, Phase II), and metabolic-dysfunction-associated steatohepatitis (miricorilant, Phase IIb).
Key quantitative points as of the latest filing: Korlym generated roughly $71 million in net sales in FY 2023, representing about 85 % of total revenue, while cash and short-term investments stood at $210 million, giving the company a runway of over two years at current burn rates. The global Cushing’s syndrome market is estimated at $1.2 billion and is projected to grow ~5 % CAGR, driven by increased diagnostic awareness and limited therapeutic options-an environment that could amplify Korlym’s market share if relacorilant succeeds. Additionally, biotech sector funding remains robust, with Q3 2024 venture capital inflows up 12 % YoY, supporting continued R&D investment for companies like Corcept.
If you want a data-driven deep-dive into CORT’s valuation assumptions and scenario analysis, ValueRay’s research platform offers tools that can help you quantify the upside and downside risks.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (105.2m TTM) > 0 and > 6% of Revenue (6% = 44.5m TTM) |
| FCFTA 0.20 (>2.0%) and ΔFCFTA 1.56pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 49.77% (prev 54.21%; Δ -4.45pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.20 (>3.0%) and CFO 162.8m > Net Income 105.2m (YES >=105%, WARN >=100%) |
| Net Debt (-118.8m) to EBITDA (72.5m) ratio: -1.64 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.14 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (119.4m) change vs 12m ago 5.03% (target <= -2.0% for YES) |
| Gross Margin 98.19% (prev 98.44%; Δ -0.25pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 92.19% (prev 80.15%; Δ 12.05pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -3.94 (EBITDA TTM 72.5m / Interest Expense TTM -17.9m) >= 6 (WARN >= 3) |
Altman Z'' 9.38
| (A) 0.45 = (Total Current Assets 541.1m - Total Current Liabilities 172.3m) / Total Assets 823.6m |
| (B) 0.75 = Retained Earnings (Balance) 619.1m / Total Assets 823.6m |
| (C) 0.09 = EBIT TTM 70.6m / Avg Total Assets 803.9m |
| (D) 3.24 = Book Value of Equity 621.6m / Total Liabilities 191.7m |
| Total Rating: 9.38 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 67.39
| 1. Piotroski 5.50pt |
| 2. FCF Yield 2.09% |
| 3. FCF Margin 21.93% |
| 4. Debt/Equity 0.01 |
| 5. Debt/Ebitda -1.64 |
| 6. ROIC - WACC (= -2.94)% |
| 7. RoE 15.99% |
| 8. Rev. Trend 96.63% |
| 9. EPS Trend 9.29% |
What is the price of CORT shares?
Over the past week, the price has changed by +2.96%, over one month by +10.15%, over three months by +15.92% and over the past year by +40.31%.
Is CORT a buy, sell or hold?
- Strong Buy: 2
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CORT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 135.3 | 62.7% |
| Analysts Target Price | 135.3 | 62.7% |
| ValueRay Target Price | 118 | 42% |
CORT Fundamental Data Overview November 26, 2025
P/E Trailing = 89.3218
P/E Forward = 35.3357
P/S = 11.048
P/B = 12.8643
P/EG = 0.61
Beta = 0.2
Revenue TTM = 741.2m USD
EBIT TTM = 70.6m USD
EBITDA TTM = 72.5m USD
Long Term Debt = 6.36m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.05m USD (from shortTermDebt, last quarter)
Debt = 6.36m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -118.8m USD (from netDebt column, last quarter)
Enterprise Value = 7.77b USD (8.19b + Debt 6.36m - CCE 421.7m)
Interest Coverage Ratio = -3.94 (Ebit TTM 70.6m / Interest Expense TTM -17.9m)
FCF Yield = 2.09% (FCF TTM 162.6m / Enterprise Value 7.77b)
FCF Margin = 21.93% (FCF TTM 162.6m / Revenue TTM 741.2m)
Net Margin = 14.19% (Net Income TTM 105.2m / Revenue TTM 741.2m)
Gross Margin = 98.19% ((Revenue TTM 741.2m - Cost of Revenue TTM 13.4m) / Revenue TTM)
Gross Margin QoQ = 97.79% (prev 98.23%)
Tobins Q-Ratio = 9.44 (Enterprise Value 7.77b / Total Assets 823.6m)
Interest Expense / Debt = 56.32% (Interest Expense 3.58m / Debt 6.36m)
Taxrate = 29.03% (4.42m / 15.2m)
NOPAT = 50.1m (EBIT 70.6m * (1 - 29.03%))
Current Ratio = 3.14 (Total Current Assets 541.1m / Total Current Liabilities 172.3m)
Debt / Equity = 0.01 (Debt 6.36m / totalStockholderEquity, last quarter 631.9m)
Debt / EBITDA = -1.64 (Net Debt -118.8m / EBITDA 72.5m)
Debt / FCF = -0.73 (Net Debt -118.8m / FCF TTM 162.6m)
Total Stockholder Equity = 657.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 12.77% (Net Income 105.2m / Total Assets 823.6m)
RoE = 15.99% (Net Income TTM 105.2m / Total Stockholder Equity 657.6m)
RoCE = 10.63% (EBIT 70.6m / Capital Employed (Equity 657.6m + L.T.Debt 6.36m))
RoIC = 7.62% (NOPAT 50.1m / Invested Capital 657.6m)
WACC = 10.56% (E(8.19b)/V(8.19b) * Re(10.57%) + (debt cost/tax rate unavailable))
Discount Rate = 10.57% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.79%
[DCF Debug] Terminal Value 71.02% ; FCFE base≈154.6m ; Y1≈167.3m ; Y5≈207.7m
Fair Price DCF = 22.89 (DCF Value 2.41b / Shares Outstanding 105.2m; 5y FCF grow 9.27% → 3.0% )
EPS Correlation: 9.29 | EPS CAGR: -12.14% | SUE: 0.33 | # QB: 0
Revenue Correlation: 96.63 | Revenue CAGR: 21.90% | SUE: -0.91 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.04 | Chg30d=-0.174 | Revisions Net=-1 | Analysts=5
EPS next Year (2026-12-31): EPS=1.23 | Chg30d=-0.740 | Revisions Net=+1 | Growth EPS=+22.9% | Growth Revenue=+40.9%
Additional Sources for CORT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle